CPhI: Biotech's automation boom is only just beginning amid huge surge in demand due to Covid-19
As automation creeps its way into the biotech and pharma manufacturing world to ensure consistent timelines in the middle of a tumultuous time for supply chains, CPhI’s annual report foresees its use to boost production of mRNA vaccines and personalized therapeutics.
The adoption of new technology that typically would have taken 10 years to implement is likely to be put to use in the next five, largely thanks to pharma looking to new partners to ensure better, more consistent and possibly cheaper medicine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
